Personalis, a leader in advanced genomics for precision oncology and Tempus, a leader in Artificial Intelligence and precision medicine, have announced a strategic collaboration to co-commercialise NeXT Personal Dx, Personalis whole genome-based liquid biopsy laboratory-developed test (LDT) for detection of molecular residual disease (MRD) and recurrence in cancer. NeXT Personal Dx is a leap forward in tumour-informed approaches, setting a new standard in performance of MRD tests with unprecedented sensitivity and high specificity. The test was launched by Personalis in October 2023.
The two companies will work together exclusively in tumour-informed MRD testing for lung cancer, as well as breast cancer and immunotherapy monitoring after clinical validation of NeXT Personal Dx in those indications. The agreement contemplates testing up to tens of thousands of new patients over the next three years.
“We believe that monitoring cancer recurrence is an important emerging development that has the potential to transform the way cancer is managed and Tempus is excited to bring this best-in-class tumour-informed test to oncologists to complement our existing tumour naïve MRD strategy,” said Eric Lefkofsky, Founder and CEO of Tempus.